PL EN


Preferences help
enabled [disable] Abstract
Number of results
2013 | 60 | 1 | 77-82
Article title

Distinct inhibitory efficiency of siRNAs and DNAzymes to β1 integrin subunit in blocking tumor growth

Content
Title variants
Languages of publication
EN
Abstracts
EN
Receptors of the β1 integrin family are involved in many tumor-promoting activities. There are several approaches currently used to control integrin activity, and thus to potentially restrain tumor metastasis and angiogenesis. In this study, we compared inhibitory efficiencies of siRNA and DNAzymes against the β1 integrin subunit (DEβ1), in a mouse xenograft model. Both inhibitors were used under their most favorable conditions, in terms of concentrations, incubation time and lack of cytotoxic effects. Transfection of siRNAβ1 or DEβ1 remarkably inhibited the growth of both PC3 and HT29 colon cancer cells in vitro, and decreased their capability of initiating tumor formation in the mouse xenograft model. siRNAβ1 appeared to be slightly more efficient than DEβ1 when tested in vitro, however it was comparably less proficient in blocking the tumor growth in vivo. We conclude the DNAzyme, due to its greater resistance to degradation in extra- and intracellular compartments, to be a superior inhibitor of tumor growth in long lasting experiments in vivo when compared to siRNA, while the latter seems to be more efficient in blocking β1 expression during in vitro experiments using cell cultures.
Publisher

Year
Volume
60
Issue
1
Pages
77-82
Physical description
Dates
published
2013
received
2012-10-02
revised
2012-12-30
accepted
2013-02-12
(unknown)
2013-03-19
Contributors
  • Department of Molecular and Medical Biophysics, Medical University of Lodz, Łódź, Poland
  • Department of Molecular and Medical Biophysics, Medical University of Lodz, Łódź, Poland
  • Department of Nephropathology, Medical University of Lodz, Łódź, Poland
  • Department of Nephropathology, Medical University of Lodz, Łódź, Poland
  • Department of Molecular and Medical Biophysics, Medical University of Lodz, Łódź, Poland
References
  • Albelda SM (1993) Role of integrins and other cell adhesion molecules in tumor progression and metastasis. Lab Invest 68: 4-17.
  • Barnes PJ (2008) Role of GATA-3 in allergic diseases. Curr Mol Med 8: 330-334.
  • Bertrand JR, Pottier M, Vekris A, Opolon P, Maksimenko A, Malvy C (2002) Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res Commun 296: 1000-1004.
  • Cieslak M, Niewiarowska J, Nawrot M, Koziolkiewicz M, Stec WJ, Cierniewski CS (2002) DNAzymes to β1 and β3 mRNA down-regulate expression of the targeted integrins and inhibit endothelial cell capillary tube formation in fibrin and matrigel. J Biol Chem 277: 6779-6787.
  • Cieslak M, Szymanski J, Adamiak RW, Cierniewski CS (2003) Structural rearrangements of the 10-23 DNAzyme to β3 integrin subunit mRNA induced by cations and their relations to the catalytic activity. J Biol Chem 278: 47987-47996.
  • Goel HL, Breen M, Zhang J, Das I, Aznavoorian-Cheshire S, Greenberg NM, Elgavish A, Languino LR (2005) β1A integrin expression is required for type 1 insulin-like growth factor receptor mitogenic and transforming activities and localization to focal contacts. Cancer Res 65: 6692-6700.
  • Goel HL, Fornaro M, Moro L, Teider N, Rhim JS, King M, Languino LR (2004) Selective modulation of type 1 insulin-like growth factor receptor signaling and functions by β1 integrins. J Cell Biol 166: 407-418.
  • Hannon GJ (2002) RNA interference. Nature 418: 244-251.
  • Holly SP, Larson MK, Parise LV (2000) Multiple roles of integrins in cell motility. Exp Cell Res 261: 69-74.
  • Hynes RO (1992) Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69: 11-25.
  • Isaka Y (2007) DNAzymes as potential therapeutic molecules. Curr Opin Mol Ther 9: 132-136.
  • Jackson AL, Bartz SR, Schelter ?., Kobayashi SV, Burchard J, Mao M, Li B, Cavet G, Linsley PS (2003) Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 21: 635-637.
  • Kohlgraf KG, Gawron AJ, Higashi M, Meza JL, Burdick MD, Kitajima S, Kelly DL, Caffrey TC, Hollingsworth MA (2003) Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line. Cancer Res 63: 5011-5020.
  • Ma WW, Adjei AA (2009) Novel agents on the horizon for cancer therapy. CA Cancer J Clin 59: 111-137.
  • Manes T, Zheng DQ, Tognin S, Woodard AS, Marchisio PC, Languino LR (2003) Alpha(v)beta3 integrin expression up-regulates cdc2, which modulates cell migration. J Cell Biol 161: 817-826.
  • Mukherjee P, Tinder TL, Basu GD, Gendler SJ (2005) MUC1 (CD227) interacts with lck tyrosine kinase in Jurkat lymphoma cells and normal T cells. J Leukoc Biol 77: 90-99.
  • Niewiarowska J, Sacewicz I, Wiktorska M, Wysocki T, Stasikowska O, Wagrowska-Danilewicz M, Cierniewski CS (2009) DNAzymes to mouse beta1 integrin mRNA in vivo: targeting the tumor vasculature and retarding cancer growth. Cancer Gene Ther 16: 713-22.
  • Petrocca F, Lieberman J (2011) Promise and challenge of RNA interference-based therapy for cancer. J Clin Oncol 29: 747-754.
  • Pignatelli M, Hanby AM, Stamp GW (1991) Low expression of β1, α2 and α3 subunits of VLA integrins in malignant mammary tumours. J Pathol 165: 25-32.
  • Rathinam R, Alahari SK (2010) Important role of integrins in the cancer biology. Cancer Metastasis Rev 29: 223-237.
  • Ren J, Agata N, Chen D, Li Y, Yu WH, Huang L, Raina D, Chen W, Kharbanda S, Kufe D (2004) Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell 5: 163-175.
  • Santoro SW, Joyce GF (1998) Mechanism and utility of an RNA-cleaving DNA enzyme. Biochemistry 37: 13330-13342.
  • Schiffelers RM, Woodle MC, Scaria P (2004) Pharmaceutical prospects for RNA interference. Pharm Res 21: 1-7.
  • Schubert S, Gul DC, Grunert HP, Zeichhardt H, Erdmann VA, Kurreck J (2003) RNA cleaving '10-23' DNAzymes with enhanced stability and activity. Nucleic Acids Res 31: 5982-5992.
  • Schubert S, Kurreck J (2004) Ribozyme- and deoxyribozyme-strategies for medical applications. Curr Drug Targets 5: 667-681.
  • Sel M, Wegmann T, Dicke S, Sel W, Henke AO, Yildirim H, Renz H, Garn H (2008) Effective prevention and therapy of experimental allergic asthma using a GATA-3-specific DNAzyme. J Allergy Clin Immunol 121: 910-916.
  • Silverman SK (2005) In vitro selection, characterization, and application of deoxyribozymes that cleave RNA. Nucleic Acids Res 33: 6151-6163.
  • Sioud M (2006) Innate sensing of self and non-self RNAs by toll-like receptors. Trends Mol Med 12: 167-176.
  • Tritz R, Habita C, Robbins JM, Gomez GG, Kruse CA (2005) Catalytic nucleic acid enzymes for the study and development of therapies in the central nervous system: review article. Gene Ther Mol Biol 9A: 89-106.
  • Uhm JH, Gladson CL, Rao JS (1999) The role of integrins in the malignant phenotype of gliomas. Front Biosci 4D: 188-199.
  • Wiktorska M, Papiewska-Pajak I, Okruszek A, Sacewicz-Hofman I, Niewiarowska J (2010) DNAzyme as an efficient tool to modulate invasiveness of human carcinoma cells. Acta Biochim Polon 57: 269-275.
  • Yazji S, Bokowski R, Kondagunta V, Figlin R (2007) Final results from phase II study of volociximab, an α5β1 anti-integrin antibody, in refractory or relapsed metastatic clear cell renal cell carcinoma (mCCRCC). J Clin Oncol 18S (Suppl): 5094 (abstract).
  • Zhu J, Yamane H, Cote-Sierra J, Guo L, Paul WE (2006) GATA-3 promotes Th2 responses through three different mechanisms: induction of Th2 cytokine production, selective growth of Th2 cells and inhibition of Th1 cell-specific factors. Cell Res 16: 3-10.
  • Zutter MM, Mazoujian G, Santoro SA (1990) Decreased expression of integrin adhesive protein receptors in adenocarcinoma of the breast. Am J Pathol 137: 863-870.
Document Type
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.bwnjournal-article-abpv60p77kz
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.